High Throughput Newborn Screening for Sickle Cell Disease – Application of Two-Tiered Testing with a qPCR-Based Primary screen

Abstract

Background Sickle cell disease (SCD) is a group of hemoglobinopathies with a common point mutation causing the production of sickle cell hemoglobin (HbS). In high-throughput newborn screening (NBS) for SCD, a two-step procedure is suitable, in which qPCR first pre-selects relevant samples that are differentiated by a second method.

Methods Three NBS centers using qPCR-based primary screening for SCD performed a laboratory comparison. Methods using tandem MS or HPLC were used for differentiation.

Results In a benchmarking test, 450 dried blood samples were analyzed. Samples containing HbS were detected as reliably by qPCR as by methods established for hemoglobinopathy testing. In a two-step screening approach, the 2^nd-tier-analyses have to distinguish the carrier status from pathological variants. In nine months of regular screening, a total of 353,219 samples were analyzed using two-stage NBS procedures. The 1^st-tier screening by qPCR reduced the number of samples for subsequent differentiation by>99.5%. Cases with carrier status or other variants were identified as inconspicuous while 78 cases with SCD were revealed. The derived incidence of 1:4,773, is in good agreement with previously published incidences.

Conclusion In high-throughput NBS for SCD, qPCR is suitable to focus 2^nd-tier analyses on samples containing HbS, while being unaffected by factors such as prematurity or transfusions. The substantial reduction of samples numbers positively impacts resource conservation, sustainability, and cost-effectiveness. No false negative cases came to attention.

Zusammenfassung

Hintergrund Die Sichelzellkrankheit (SCD) bezeichnet eine Gruppe von Hämoglobinopathien mit einer gemeinsamen Punktmutation, die zur Bildung von Sichelzell-Hämoglobin (HbS) führt. Für das Hochdurchsatz-Neugeborenenscreening (NGS) auf SCD bietet sich ein zweistufiges Verfahren an, in dem die qPCR HbS-haltige Proben vorselektiert, die mit einer zweiten Methode differenziert werden.

Methoden Drei NGS-Zentren, in denen ein qPCR-basiertes Primärscreening auf SCD durchgeführt wird, haben sich einem Laborvergleich unterzogen. Zur Differenzierung wurden Tandem-MS oder HPLC genutzt.

Ergebnisse In einem Laborvergleich mit 450 Trockenblutproben wurden HbS-haltige Proben mit qPCR ebenso zuverlässig erkannt, wie mit Methoden die zur Untersuchung von Hämoglobinopathien etabliert sind. Der Fokus der Folgeanalytik liegt beim zweistufigen SCD Screening somit auf der Unterscheidung zwischen Trägerstatus und pathologischen Varianten. In neun Monaten Regelscreening wurden insgesamt 353.219 Proben untersucht, wobei das 1^st-tier-NGS mittels qPCR die Probenzahl für die Differenzierung um>99,5% reduzierte. Fälle mit Trägerstatus oder andere Varianten wurden als unauffällig erkannt und 78 Fälle mit SCD diagnostiziert. Die abgeleitete Inzidenz von 1:4.773, stimmt gut mit bislang publizierten Inzidenzen überein.

Schlussfolgerung Im Hochdurchsatz-NGS auf SCD ist qPCR geeignet, um die Folgeanalytik auf Proben zu fokussieren, die HbS enthalten und dabei von Störkonstellationen wie Frühgeburtlichkeit oder Transfusionen unbeeinflusst zu sein. Die erhebliche Reduzierung der Probenzahl wirkt sich positiv auf Ressourcenschonung, Nachhaltigkeit und Wirtschaftlichkeit aus. Falsch negative Befunde sind nicht bekannt geworden.

Key words

newborn screening - sickle cell disease - two-tiered testing - qPCR - benchmarking - high-throughput screening

Schlüsselwörter

Neugeborenenscreening - Sichelzellkrankheit - zweistufige Diagnostik - qPCR - Laborvergleich - Hochdurchsatz-Screening

Publication History

Article published online:
25 September 2023

• References

• 1 Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. J Hematol Oncol 2022; 15: 20 DOI: 10.1186/s13045-022-01237-z.
• 2 An R, Huang Y, Rocheleau A. et al. Multispectral imaging for MicroChip electrophoresis enables point-of-care newborn hemoglobin variant screening. Heliyon 2022; 8: e11778 DOI: 10.1016/j.heliyon.2022.e11778.
• 3 Kato GJ, Piel FB, Reid CD. et al. Sickle cell disease. Nat Rev Dis Primers 2018; 4: 18010 DOI: 10.1038/nrdp.2018.10.
• 4 Ware RE, de Montalembert M, Tshilolo L. et al. Sickle cell disease. The Lancet 2017; 390: 311-323 DOI: 10.1016/S0140-6736(17)30193-9.
• 5 Ryan K, Bain BJ, Worthington D. et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol 2010; 149: 35-49 DOI: 10.1111/j.1365-2141.2009.08054.x.
• 6 Tanhehco YC, Nathu G, Vasovic LV. Development of curative therapies for sickle cell disease. Front Med 2022; 9: 1055540 DOI: 10.3389/fmed.2022.1055540.
• 7 Lobitz S, Telfer P, Cela E. et al. Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference. Br J Haematol 2018; 183: 648-660 DOI: 10.1111/bjh.15600.
• 8 Loeber JG, Platis D, Zetterström RH. et al. Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010. Int J Neonatal Screen 2021; 7 DOI: 10.3390/ijns7010015.
• 9 Daniel Y, Elion J, Allaf B. et al. Newborn Screening for Sickle Cell Disease in Europe. Int J Neonatal Screen 2019; 5: 15 DOI: 10.3390/ijns5010015.
• 10 González-Irazabal Y, Hernandez de Abajo G, Martínez-Morillo E.. Identifying and overcoming barriers to harmonize newborn screening programs through consensus strategies. Crit Rev Clin Lab Sci 2021; 58: 29-48 DOI: 10.1080/10408363.2020.1781778.
• 11 Chace DH, Hannon WH. Impact of second-tier testing on the effectiveness of newborn screening. Clin Chem 2010; 56: 1653-1655 DOI: 10.1373/clinchem.2010.153494.
• 12 Lobitz S, Klein J, Brose A. et al. Newborn screening by tandem mass spectrometry confirms the high prevalence of sickle cell disease among German newborns. Ann Hematol 2019; 98: 47-53 DOI: 10.1007/s00277-018-3477-4.
• 13 Czibere L, Burggraf S, Fleige T. et al. High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qPCR. Eur J Hum Genet 2020; 28: 23-30 DOI: 10.1038/s41431-019-0476-4.
• 14 Kunz JB, Awad S, Happich M. et al. Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening. Ann Hematol 2016; 95: 397-402 DOI: 10.1007/s00277-015-2573-y.
• 15 Brockow I, Blankenstein O, Ceglarek U. et al. Nationaler Screeningreport Deutschland 2020. DGNS; . 2022
• 16 Tesorero R, Janda J, Hörster F. et al. A high-throughput newborn screening approach for SCID, SMA, and SCD combining multiplex qPCR and tandem mass spectrometry. PLOS ONE 2023; 18: e0283024 DOI: 10.1371/journal.pone.0283024.
• 17 Frömmel C. Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies: A Short Review on Classical Laboratory Methods—Isoelectric Focusing, HPLC, and Capillary Electrophoresis. Int J Neonatal Screen 2018; 4: 39 DOI: 10.3390/ijns4040039.
• 18 Boemer F, Cornet Y, Libioulle C. et al. 3-years experience review of neonatal screening for hemoglobin disorders using tandem mass spectrometry. Clin Chim Acta 2011; 412: 1476-1479 DOI: 10.1016/j.cca.2011.04.031.
• 19 Pattloch D. Sichelzellkrankheit unter Neugeborenen in Deutschland: Eine Studie an Routinedaten der AOK. Gesundheitswesen 2019; 81: 986-992 DOI: 10.1055/a-0719-5165.
• 20 Frömmel C, Brose A, Klein J. et al. Newborn screening for sickle cell disease: technical and legal aspects of a German pilot study with 38,220 participants. Biomed Res Int 2014; 2014: 695828 DOI: 10.1155/2014/695828.
• 21 Grosse R, Lukacs Z, Cobos PN. et al. The Prevalence of Sickle Cell Disease and Its Implication for Newborn Screening in Germany (Hamburg Metropolitan Area). Pediatr Blood Cancer 2016; 63: 168-170 DOI: 10.1002/pbc.25706.
• 22 Lobitz S, Frömmel C, Brose A. et al. Incidence of sickle cell disease in an unselected cohort of neonates born in Berlin, Germany. Eur J Hum Genet 2014; 22: 1051-1053 DOI: 10.1038/ejhg.2013.286.
• 23 GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1204-1222 DOI: 10.1016/S0140-6736(20)30925-9.
• 24 Olatunya OS, Babatola AO, Ogundare EO. et al. Perceptions and Practice of Early Diagnosis of Sickle Cell Disease by Parents and Physicians in a Southwestern State of Nigeria. ScientificWorldJournal 2020; 2020: 4801087 DOI: 10.1155/2020/4801087.
• 25 Ranque B, Kitenge R, Ndiaye DD. et al. Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study. Lancet Haematol 2022; 9: e208-e216 DOI: 10.1016/S2352-3026(22)00004-7.
• 26 Arishi WA, Alhadrami HA, Zourob M. Techniques for the Detection of Sickle Cell Disease: A Review. Micromachines (Basel) 2021; 12 DOI: 10.3390/mi12050519.